Q-omics provides the consensus-scored TAL2 profile across patient tissues and cancer cell-line models. TAL2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TAL2 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, TAL2 RNA expression shows 16,764 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where TAL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAL2 survival associations across molecular data types. TAL2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAL2 RNA expression–survival associations across cancer types. High TAL2 expression shows unfavorable associations in UVM, BLCA and STAD, but favorable associations in KIRC, UCS and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TAL2 RNA expression.
This table summarizes TAL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TAL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAL2 shows lower tumor expression in KICH and KIRP and higher tumor expression in LIHC, KIRC, COAD and READ. The KICH box plot shows higher TAL2 RNA expression in normal versus tumor tissue (log2 FC = −2.634, t-test p < 0.001).
This table shows molecular features associated with TAL2 in patient tissues and cancer cell lines. In patient samples, TAL2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TAL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and CNS.
